Nitresan (Nitrendipine)

Nitrendipine belongs to the dihydropyridine class of calcium channel blockers. It selectively blocks L‑type calcium channels in vascular smooth‑muscle cells, preventing calcium influx that is necessary for contraction. This inhibition causes vasodilation, decreases peripheral vascular resistance, and ultimately lowers arterial blood pressure.

The dosage of Nitresan is individualized by the prescribing healthcare professional based on the patient’s clinical condition, response to therapy, and any concomitant medications. The prescriber determines the appropriate strength, frequency, and duration of treatment in accordance with local guidelines and product labeling.

Safety data for nitrendipine in pregnancy and lactation are limited, and the product’s pregnancy category has not been established. It should only be used if the potential benefit justifies the possible risk to the fetus. Breastfeeding mothers should consult their physician, as the drug may be excreted in milk.

To request Nitresan, visit the product page on gnhindia.com, enter the desired quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any required import documentation.

Compared with non‑dihydropyridine calcium channel blockers, nitrendipine primarily causes arterial vasodilation with minimal effect on cardiac conduction. It differs from ACE inhibitors or ARBs, which act on the renin‑angiotensin system, and from beta‑blockers, which reduce heart rate. Choice of therapy depends on patient profile, comorbidities, and tolerance.

Nitresan tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments to maintain stability.

Nitresan is taken orally, usually with a glass of water. It may be taken with or without food, but patients should follow the prescriber’s instructions regarding timing and any dietary considerations to ensure consistent absorption.

The most serious adverse events include severe hypotension, myocardial infarction, life‑threatening arrhythmias, hepatic dysfunction, and severe skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience fainting, chest pain, irregular heartbeat, jaundice, or widespread rash.

Nitresan is contraindicated in patients with known hypersensitivity to nitrendipine or other dihydropyridine calcium channel blockers. It should also be avoided in individuals with severe aortic stenosis, unstable angina, or acute myocardial infarction, and in those where significant drug interactions could lead to dangerous hypotension.